AGO1 may influence the prognosis of hepatocellular carcinoma through TGF-β pathway

Area of Science:

• Molecular Biology
• Oncology
• Gene Regulation

Background:

• Argonaute 1 (AGO1) is integral to RNA-induced silencing complexes and implicated in various solid tumors.
• Hepatocellular carcinoma (HCC) is a significant global health concern with complex metastatic pathways.
• Understanding AGO1's role in HCC progression is crucial for identifying therapeutic targets and prognostic markers.

Purpose of the Study:

• To elucidate the specific functions of AGO1 in hepatocellular carcinoma (HCC) progression.
• To investigate the molecular mechanisms by which AGO1 influences HCC cell behavior, including proliferation, migration, and invasion.
• To evaluate the prognostic significance of AGO1 expression in HCC patients.

Main Methods:

• Utilized small interfering RNA (siRNA) to deplete AGO1 in HCCLM3 cell lines.
• Assessed cell proliferation, migration, and invasion using MTT, wound-healing, and Transwell assays.
• Analyzed epithelial-mesenchymal transition (EMT) markers and signaling pathway activation via Western blot and immunohistochemistry.

Main Results:

• AGO1 depletion significantly inhibited HCC cell proliferation, migration, and invasion.
• Knockdown of AGO1 led to increased E-cadherin and decreased N-cadherin, Vimentin, Snail, and Zeb1, suggesting EMT suppression.
• AGO1 inhibition affected ERK1/2 and Smad signaling pathways, impacting Snail transcription and subsequent cell invasion.

Conclusions:

• AGO1 promotes HCC metastasis, likely through the TGF-β pathway by influencing EMT.
• Intratumoral AGO1 expression serves as an independent risk factor for poor overall and recurrence-free survival in HCC patients.
• AGO1 represents a potential therapeutic target and a reliable prognostic biomarker for hepatocellular carcinoma.